Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:03 PM
Ignite Modification Date: 2025-12-24 @ 1:03 PM
NCT ID: NCT00636961
Eligibility Criteria: Inclusion Criteria: * Male and female subjects, * 40 to 80 years of age, * with a documented diagnosis of mild, moderate or severe chronic obstructive pulmonary disease (COPD) according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and \>20-pack year history of smoking, a post-bronchodilator 40% ≤ FEV1 ≤ 80% of predicted normal and post-bronchodilator FEV1/FVC \< 70% who have signed an informed consent form (ICF) prior to the initiation of any study-related procedure (Post bronchodilator refers to 30 minutes after the inhalation of 400 µg of salbutamol) * Subjects who demonstrate a plethysmographic functional residual capacity \>120% predicted normal Exclusion Criteria: * No COPD exacerbations within 6 weeks prior to dosing, * no concomitant lung disease such as asthma, * no requirement for long term oxygen treatment or history of lung reduction surgery. * No medical conditions that would interfere with the performance of spirometry or clinical exercise testing. * Any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from participating in the study e.g. uncontrolled hypertension or unstable ischemic heart disease Other protocol-defined inclusion/exclusion criteria may apply
Healthy Volunteers: False
Sex: ALL
Minimum Age: 40 Years
Maximum Age: 80 Years
Study: NCT00636961
Study Brief:
Protocol Section: NCT00636961